Proteina Presents Comparative Data with Leading Drug at EULAR 2026

Proteina, a specialized AI drug discovery company based on protein-protein interaction (PPI) big data, announced on June 8 that it unveiled preclinical comparative data for its osteoarthritis treatment candidate 'PRT-101' at the European Alliance of Associations for Rheumatology (EULAR 2026). EULAR 2026 was held in London, United Kingdom from June 3 to 6, local time.

The PRT-101 study by Proteina was selected for the 'Poster Tour' session, which features research of high academic value within the conference, and was separately presented to global experts. During this session, for the first time, results from a direct nonclinical comparative study with 'Lorecivivint,' an osteoarthritis treatment candidate under Phase 3 clinical development by the U.S. company Biosplice, were unveiled.

Dr. Ahn Junghyun from Proteena is presenting the EULAR 2026 poster tour. Proteena

PRT-101 is a first-in-class innovative drug candidate with a novel mechanism that directly targets the SOX9 protein, a key transcription factor for cartilage formation, to promote protein aggregation and induce cartilage regeneration. The company previously presented initial preclinical data at the Osteoarthritis Research Society International (OARSI 2026) in the United States in April.

In comparative studies using severe osteoarthritis animal models, PRT-101 demonstrated superior efficacy over Lorecivivint across key evaluation criteria, including cartilage regeneration and structural maintenance, pain relief, restoration of motor function, and improvement of the inflammatory environment. Notably, the study confirmed not only inhibition of disease progression but also the potential for recovery of damaged joint tissue, highlighting PRT-101's potential to become a next-generation disease-modifying osteoarthritis drug (DMOAD) and a best-in-class treatment in its category.

The company explained that during on-site partnering meetings with multiple international pharmaceutical firms, there was continued interest in both the completeness of PRT-101's preclinical data and Proteina's proprietary drug discovery platform, SPID. Given the high global demand for novel mechanism-based treatments in the osteoarthritis market, where no DMOADs currently exist, discussions regarding future licensing out (LO) and joint development are expected to accelerate.

A Proteina representative stated, "The data unveiled at EULAR 2026 demonstrates PRT-101's potential to grow into the next-generation DMOAD and best-in-class treatment," adding, "Having proven our data competitiveness and R&D capabilities to global pharmaceutical companies, we plan to accelerate discussions on licensing out and global commercialization going forward."

This content was produced with the assistance of AI translation services.